DPP-4

Assets acting on this target.

Class
Dipeptidyl peptidase-4 inhibitor

Dipeptidyl peptidase-4 (DPP-4) is an enzyme present on the surface of many cell types and circulating in blood, where it rapidly breaks down a class of gut-derived hormones called incretins, principally glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones are released after meals and help the pancreas release insulin in a glucose-dependent manner while suppressing glucagon, a hormone that raises blood sugar. By inhibiting DPP-4, drugs in this class prolong the activity of endogenous incretins, leading to improved insulin secretion and reduced glucagon output after eating, without directly stimulating insulin release independent of glucose levels. This mechanism is central to the management of type 2 diabetes, where impaired incretin signaling and insulin resistance contribute to elevated blood glucose. Because DPP-4 inhibition works through amplifying a natural, glucose-sensitive pathway rather than forcing insulin release, it is generally associated with a lower risk of hypoglycemia compared to some older glucose-lowering approaches. The enzyme's broad distribution across immune, renal, and endothelial tissue also underlies ongoing interest in effects beyond glycemic control, though the primary rationale for this drug class remains restoration of postprandial incretin activity in diabetes care.

By indication

Related mechanisms

DPP-4 drugs compared

17 drugs, stage by indication
17 drugs acting on DPP-4: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
AlogliptinNesinaTakeda Pharmaceutical Company, Teijinsmall moleculeApprovedApproved in Type 2 Diabetes
LinagliptinTradjentaBoehringer Ingelheim, Eli Lillysmall moleculeApprovedApproved in Type 2 Diabetes
SaxagliptinOnglyzaAstraZeneca, Kyowa Kirinsmall moleculeApprovedApproved in Type 2 Diabetes
SitagliptinJanuviaMerck & Co., Ono Pharmaceuticalsmall moleculeApprovedApproved in Type 2 Diabetes
AnagliptinSuinyJW Pharmaceutical, Kowa Company, Ltd., Sanwa Kagaku Kenkyushosmall moleculePhase 3Phase 3 in Type 2 Diabetes
CofrogliptinHaisco Pharmaceutical Groupsmall moleculePhase 3Phase 3 in Type 2 Diabetes
EvogliptinSuganonAlkem Laboratories, Dong-A ST, Eurofarma Laboratorios, Geropharm, Luye Pharma Group, Rednviasmall moleculePhase 3Phase 3 in Type 2 Diabetes
GemigliptinZemigloChina Resources Double-Crane Pharmaceutical, Daewoong Pharmaceutical, LG Chem, Sanofi, Stendhalsmall moleculePhase 3Phase 3 in Type 2 Diabetes
GosogliptinSatRxsmall moleculePhase 3Phase 3 in Type 2 Diabetes
OmarigliptinMarizevKissei Pharmaceutical, Merck & Co.small moleculePhase 3Not recorded
PrusogliptinShanzepingCSPC Pharmaceutical Group, Genovate Biotechnologysmall moleculePhase 3Phase 3 in Type 2 Diabetes
RetagliptinJiangsu Hengrui Pharmaceuticalssmall moleculePhase 3Phase 3 in Type 2 Diabetes
TeneligliptinTeneliaHandok, Servier, Tanabe Pharma Corporationsmall moleculePhase 3Phase 3 in Type 2 Diabetes
TrelagliptinZafatekTakeda Pharmaceutical Company, Teijinsmall moleculePhase 3Phase 3 in Type 2 Diabetes
VildagliptinGalvusCipla, Novartis, Sumitomo Pharmasmall moleculePhase 3Phase 3 in Type 2 Diabetes
YogliptinChengdu Easton Biopharmaceuticalssmall moleculePhase 3Phase 3 in Type 2 Diabetes
Retagliptin/metformin (Ruilintang)RuilintangJiangsu Hengrui Pharmaceuticalssmall molecule combinationPhase 1Phase 1 in Type 2 Diabetes

← all mechanisms